Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia
ثبت نشده
چکیده
Draft Agreed by Central Nervous System Working Party January 2011 Draft Agreed by Biostatistics Working Party February 2011 Adoption by CHMP for release for consultation February 2011 End of consultation (deadline for comments) 31 August 2011 Agreed by Central Nervous System Working Party September 2012 Agreed by Biostatistics Working Party September 2012 Agreed by PDCO September 2012 Adoption by CHMP 20 September 2012 Date for coming into effect 1 April 2013
منابع مشابه
Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD)
Keywords Chronic obstructive pulmonary disease (COPD), airflow obstruction, relief of symptoms, maintenance treatment, exacerbations. 1 correction related to a change on p. 4 Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD) EMA/CHMP/700491/2012 2/17 Guideline on clinical investigation of medicinal products in the treatmen...
متن کاملGuideline on clinical investigation of medicinal products in the treatment of lipid disorders
This guideline replaces the ‘Note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders (CPMP/EWP/3020/03)’. Rev. 1 and Rev. 2 were combined: Rev. 1 was regarding imaging surrogate endpoints Rev. 2 was regarding the need for outcome studies based on safety data at the time of Marketing Authorisation Application.
متن کامل